ABSTRACT
BACKGROUND: Currently, the most dynamic areas in the glutamate receptor system neurobiology are the identification and development of positive allosteric modulators (PAMs) of glutamate ionotropic receptors. PAM-based drugs are of great interest as promising candidates for the treatment of neurological diseases, such as epilepsy, Alzheimer's disease, schizophrenia, etc. Understanding the molecular mechanisms underlying the biological action of natural and synthetic PAMs is a key point for modifying the original chemical compounds as well as for new drug design. OBJECTIVE: We are trying to elaborate a system of molecular functional screening of ionotropic glutamate receptor probable PAMs. METHODS: The system will be based on the radioligand - receptor method of analysis and will allow rapid quantification of new AMPAR probable PAMs molecular activity. We plan to use a tritiumlabeled analogue of recently elaborated ionotropic GluR probable PAM ([3H]PAM-43) as the main radioligand. RESULTS: Here, we characterized the specific binding of the ligand and its ability to potentiate ionotropic GluR currents. The existence of at least two different sites of [3H]PAM-43 specific binding has been shown. One of the above sites is glutamate-dependent and is characterized by higher affinity. "Patchclamp" technique showed the ability of PAM-43 to potentiate ionotropic GluR currents in rat cerebellar Purkinje neurons in a concentration-dependent manner. CONCLUSION: The possibility of using PAM-43 as a model compound to study different allosteric effects of potential regulatory drugs (AMPAR allosteric regulators) was shown. [3H]PAM-43 based screening system will allow rapid selection of new AMPAR probable PAM structures and quantification of their molecular activity.
Subject(s)
Excitatory Amino Acid Agonists/pharmacology , Purkinje Cells/drug effects , Receptors, AMPA/agonists , Action Potentials/drug effects , Allosteric Regulation , Allosteric Site , Animals , Animals, Outbred Strains , Binding Sites , Excitatory Amino Acid Agonists/chemistry , Humans , Ligands , Male , Molecular Structure , Patch-Clamp Techniques , Purkinje Cells/physiology , Radioligand Assay , RatsABSTRACT
α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors produce postsynaptic current by transmitting an agonist-induced structural change in the ligand-binding domain (LBD) to the transmembrane channel. Receptors carrying T686S/A substitutions in their LBDs produce weaker glutamate-evoked currents than wild-type (WT) receptors. However, the substitutions induce little differences in the crystal structures of their LBDs. To understand the structural mechanism underlying reduced activities of these AMPAR variants, we analyzed the structural dynamics of WT, T686S, and T686A variants of LBD using nuclear magnetic resonance. The HD exchange studies of the LBDs showed that the kinetic step where the ligand-binding cleft closes was changed by the substitutions, and the substitution-induced population shift from cleft-closed to cleft-open structures is responsible for the reduced activities of the variants. The chemical shift analyses revealed another structural equilibrium between cleft-locked and cleft-partially-open conformations. The substitution-induced population shift in this equilibrium may be related to slower desensitization observed for these variants.
Subject(s)
Amino Acid Substitution , Receptors, AMPA/chemistry , Binding Sites , Excitatory Amino Acid Agonists/chemistry , Excitatory Amino Acid Agonists/metabolism , Humans , Molecular Dynamics Simulation , Protein Binding , Receptors, AMPA/agonists , Receptors, AMPA/genetics , Receptors, AMPA/metabolismABSTRACT
α-amino-3-hydroxy-5-methyl-4-isoaxazolepropionic acid (AMPA) ionotropic glutamate receptors mediate fast excitatory neurotransmission in the central nervous system, and their dysfunction is associated with neurological diseases. Glutamate binding to ligand-binding domains (LBDs) of AMPA receptors induces channel opening in the transmembrane domains of the receptors. The T686A mutation reduces glutamate efficacy so that the glutamate behaves as a partial agonist. The crystal structures of wild-type and mutant LBDs are very similar and cannot account for the observed behavior. To elucidate the molecular mechanism inducing partial agonism of the T686A mutant, we computed the free-energy landscapes governing GluA2 LBD closure using replica-exchange umbrella sampling simulations. A semiclosed state, not observed in crystal structures, appears in the mutant during simulation. In this state, the LBD cleft opens slightly because of breaking of interlobe hydrogen bonds, reducing the efficiency of channel opening. The energy difference between the LBD closed and semiclosed states is small, and transitions between the two states would occur by thermal fluctuations. Evidently, glutamate binding to the T686A mutant induces a population shift from a closed to a semiclosed state, explaining the partial agonism in the AMPA receptor.
Subject(s)
Molecular Docking Simulation , Receptors, AMPA/chemistry , Amino Acid Substitution , Animals , Binding Sites , Excitatory Amino Acid Agonists/chemistry , Excitatory Amino Acid Agonists/metabolism , Glutamic Acid/chemistry , Glutamic Acid/metabolism , Humans , Hydrogen Bonding , Protein Binding , Receptors, AMPA/agonists , Receptors, AMPA/genetics , Receptors, AMPA/metabolismABSTRACT
The metabotropic glutamate 7 (mGlu7) receptor belongs to the group III of mGlu receptors. Since the mGlu7 receptor can control excitatory neurotransmission in the hippocampus and cortex, modulation of the receptor may have therapeutic benefit in several CNS diseases. However, mGlu7 remains relatively unexplored among the eight known mGlu receptors partly because of the limited availability of tool compounds to interrogate its potential therapeutic utility. Here we report the discovery of a new class of mGlu7 allosteric agonists. Hits originating from virtual screening were followed up with further analogue searching and screening, leading to a novel series of mGlu7 allosteric agonists. Guided by docking into a structural model of the mGlu7 receptor the initial hit 5 was successfully optimized to analogues with comparable potencies and more attractive drug-like attributes than AMN082.
Subject(s)
Excitatory Amino Acid Agonists/chemistry , Excitatory Amino Acid Agonists/pharmacology , Molecular Docking Simulation/methods , Receptors, Metabotropic Glutamate/agonists , Receptors, Metabotropic Glutamate/chemistry , Allosteric Regulation/drug effects , Allosteric Regulation/physiology , Animals , CHO Cells , Cricetinae , Cricetulus , Humans , Microsomes, Liver/drug effects , Microsomes, Liver/metabolism , Rats , Receptors, Metabotropic Glutamate/metabolismABSTRACT
Positive modulators of NMDA receptors are important candidates for therapeutic development to treat psychiatric disorders including autism and schizophrenia. Sulfated neurosteroids have been studied as positive allosteric modulators of NMDA receptors for years, but we understand little about the cellular fate of these compounds, an important consideration for drug development. Here we focus on a visualizable sulfated neurosteroid analogue, KK-169. As expected of a pregnenolone sulfate analogue, the compound strongly potentiates NMDA receptor function, is an antagonist of GABAA receptors, exhibits occlusion with pregnenolone sulfate potentiation, and requires receptor domains important for pregnenolone sulfate potentiation. KK-169 exhibits somewhat higher potency than the natural parent, pregnenolone sulfate. The analogue contains a side-chain alkyne group, which we exploited for retrospective click labeling of neurons. Although the anionic sulfate group is expected to hinder cell entry, we detected significant accumulation of KK-169 in neurons with even brief incubations. Adding a photolabile diazirine group revealed that the expected plasma membrane localization of KK-169 is likely lost during fixation. Overall, our studies reveal new facets of the structure-activity relationship of neurosteroids at NMDA receptors, and their intracellular distribution suggests that sulfated neurosteroids could have unappreciated targets in addition to plasma membrane receptors.
Subject(s)
Cell Membrane/drug effects , Cytoplasm/drug effects , Excitatory Amino Acid Agonists/pharmacology , Receptors, N-Methyl-D-Aspartate/agonists , Allosteric Regulation , Animals , Cell Membrane/metabolism , Cells, Cultured , Click Chemistry , Cytoplasm/metabolism , Excitatory Amino Acid Agonists/chemistry , Glutamic Acid/metabolism , Hippocampus/drug effects , Hippocampus/metabolism , Humans , Mice , Oocytes , Rats, Sprague-Dawley , Receptors, N-Methyl-D-Aspartate/metabolism , Structure-Activity Relationship , Synaptic Transmission/drug effects , Synaptic Transmission/physiology , Xenopus laevisABSTRACT
Metabotropic glutamate receptors belong to class C G-protein-coupled receptors and consist of eight subtypes that are ubiquitously expressed throughout the central nervous system. In recent years, the metabotropic glutamate receptor subtype 5 (mGlu5) has emerged as a promising target for a broad range of psychiatric and neurological disorders. Drug discovery programs targetting mGlu5 are primarily focused on development of allosteric modulators that interact with sites distinct from the endogenous agonist glutamate. Significant efforts have seen mGlu5 allosteric modulators progress into clinical trials; however, recent failures due to lack of efficacy or adverse effects indicate a need for a better understanding of the functional consequences of mGlu5 allosteric modulation. Biased agonism is an interrelated phenomenon to allosterism, describing how different ligands acting through the same receptor can differentially influence signaling to distinct transducers and pathways. Emerging evidence demonstrates that allosteric modulators can induce biased pharmacology at the level of intrinsic agonism as well as through differential modulation of orthosteric agonist-signaling pathways. Here, we present key considerations in the discovery and development of mGlu5 allosteric modulators and the opportunities and pitfalls offered by biased agonism and modulation.
Subject(s)
Central Nervous System Agents/pharmacology , Central Nervous System/drug effects , Excitatory Amino Acid Agonists/pharmacology , Receptor, Metabotropic Glutamate 5/drug effects , Signal Transduction/drug effects , Animals , Binding Sites , Central Nervous System/metabolism , Central Nervous System Agents/chemistry , Central Nervous System Agents/metabolism , Excitatory Amino Acid Agonists/chemistry , Excitatory Amino Acid Agonists/metabolism , Glutamic Acid/metabolism , Humans , Ligands , Protein Binding , Protein Conformation , Receptor, Metabotropic Glutamate 5/chemistry , Receptor, Metabotropic Glutamate 5/metabolism , Structure-Activity RelationshipABSTRACT
Receptors of glutamic acid are known for over 30 years for their action and for about 20 years for their structure. Presence of at least three classes of ionotropic receptors was confirmed at the beginning of 80'. Recognition of the sequence and first cloning were done at the beginning of 90'. In 1994 ligand binding site was recognized at the junction of two subunits S1-S2 in the ligand-binding domain. Since then, many subtypes of ionotropic and metabotropic glutamate receptors were recognized, together with their localization and functions. In the meantime numerous orthosteric ligands, both agonists and antagonists were developed especially for NMDA ion channels. Their usefulness as drugs was rather low, due to the involvement in the excitatory tract. More interest was focused on metabotropic receptors, which are GPSR's and can be modulated both by orthosteric and allosteric modulators. It seems like allosterism could be considered as promising future for glutamate receptors and ion channels, especially when first allosteric negative modulators of the mGluR2 went close into the clinical trial.
Subject(s)
Excitatory Amino Acid Agonists/pharmacology , Excitatory Amino Acid Antagonists/pharmacology , Receptors, Glutamate/metabolism , Animals , Dose-Response Relationship, Drug , Excitatory Amino Acid Agonists/chemistry , Excitatory Amino Acid Antagonists/chemistry , Humans , Models, Molecular , Structure-Activity RelationshipABSTRACT
The cyanobacterial toxin ß-N-methylamino-L-alanine (BMAA) now appears to be a cause of Guamanian amyotrophic lateral sclerosis/parkinsonism dementia complex (ALS/PDC). Its production by cyanobacteria throughout the world combined with multiple mechanisms of BMAA neurotoxicity, particularly to vulnerable subpopulations of motor neurons, has significantly increased interest in investigating exposure to this non-protein amino acid as a possible risk factor for other forms of neurodegenerative illness. We here provide a brief overview of BMAA studies and provide an introduction to this collection of scientific manuscripts in this special issue on BMAA.
Subject(s)
Amino Acids, Diamino/toxicity , Amyotrophic Lateral Sclerosis/chemically induced , Excitatory Amino Acid Agonists/toxicity , Parkinsonian Disorders/chemically induced , Amino Acids, Diamino/chemistry , Amyotrophic Lateral Sclerosis/epidemiology , Animals , Cyanobacteria Toxins , Excitatory Amino Acid Agonists/chemistry , Humans , Parkinsonian Disorders/epidemiologyABSTRACT
AMPA receptors mediate fast excitatory neurotransmission in the mammalian brain and transduce the binding of presynaptically released glutamate to the opening of a transmembrane cation channel. Within the postsynaptic density, however, AMPA receptors coassemble with transmembrane AMPA receptor regulatory proteins (TARPs), yielding a receptor complex with altered gating kinetics, pharmacology, and pore properties. Here, we elucidate structures of the GluA2-TARP γ2 complex in the presence of the partial agonist kainate or the full agonist quisqualate together with a positive allosteric modulator or with quisqualate alone. We show how TARPs sculpt the ligand-binding domain gating ring, enhancing kainate potency and diminishing the ensemble of desensitized states. TARPs encircle the receptor ion channel, stabilizing M2 helices and pore loops, illustrating how TARPs alter receptor pore properties. Structural and computational analysis suggests the full agonist and modulator complex harbors an ion-permeable channel gate, providing the first view of an activated AMPA receptor.
Subject(s)
Calcium Channels/chemistry , Receptors, AMPA/chemistry , Animals , Cryoelectron Microscopy , Excitatory Amino Acid Agonists/chemistry , Excitatory Amino Acid Agonists/pharmacology , Kainic Acid/chemistry , Kainic Acid/pharmacology , Models, Molecular , Quisqualic Acid/chemistry , Quisqualic Acid/pharmacology , Rats , Receptors, AMPA/agonistsABSTRACT
Positive allosteric modulators of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) are small molecules that decrease deactivation of AMPARs via an allosteric site. These molecules keep the receptor in an active state. Interestingly, this type of modulator has been proposed for treating cognitive decline in ageing, dementias, and Alzheimer's disease (AD). S 47445 (8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3H-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione) is a novel AMPAR positive allosteric modulator (AMPA-PAM). Here, the mechanisms by which S 47445 could improve synaptic strength and connectivity were studied and compared between young and old mice. A single oral administration of S 47445 at 10 mg/kg significantly increased long-term potentiation (LTP) in CA3-CA1 hippocampal synapses in alert young mice in comparison to control mice. Moreover, chronic treatment with S 47445 at 10 mg/kg in old alert animals significantly counteracted the deficit of LTP due to age. Accordingly, chronic treatment with S 47445 at 10 mg/kg seems to preserve synaptic cytoarchitecture in old mice as compared with young control mice. It was shown that the significant decreases in number and size of pre-synaptic buttons stained for VGlut1, and post-synaptic dendritic spines stained for spinophilin, observed in old mice were significantly prevented after chronic treatment with 10 mg/kg of S 47445. Altogether, by its different effects on LTP, VGlut1-positive particles, and spinophilin, S 47445 is able to modulate both the structure and function of hippocampal excitatory synapses known to be involved in learning and memory processes. These results open a new window for the treatment of specific age-dependent cognitive decline and dementias such as AD.
Subject(s)
Aging/drug effects , Benzoxazines/pharmacology , Excitatory Amino Acid Agonists/pharmacology , Hippocampus/drug effects , Long-Term Potentiation/drug effects , Synapses/drug effects , Triazines/pharmacology , Aging/metabolism , Aging/pathology , Animals , Benzoxazines/chemistry , Excitatory Amino Acid Agonists/chemistry , Frontal Lobe/drug effects , Frontal Lobe/metabolism , Frontal Lobe/pathology , Hippocampus/metabolism , Hippocampus/pathology , Humans , Long-Term Potentiation/physiology , Male , Mice, Inbred C57BL , Microfilament Proteins/metabolism , Molecular Structure , Nerve Tissue Proteins/metabolism , Oocytes , Receptors, AMPA/agonists , Receptors, AMPA/metabolism , Synapses/metabolism , Synapses/pathology , Triazines/chemistry , Vesicular Glutamate Transport Protein 1/metabolism , Xenopus laevisABSTRACT
A new algorithm for comparison of protein dynamics is presented. Compared protein structures are superposed and their modes of motions are calculated using the anisotropic network model. The obtained modes are aligned using the dynamic programming algorithm of Needleman and Wunsch, commonly used for sequence alignment. Dynamical comparison of hemoglobin in the T and R2 states reveals that the dynamics of the allosteric effector 2,3-bisphosphoglycerate binding site is different in the two states. These differences can contribute to the selectivity of the effector to the T state. Similar comparison of the ionotropic glutamate receptor in the kainate+(R,R)-2b and ZK bound states reveals that the kainate+(R,R)-2b bound states slow modes describe upward motions of ligand binding domain and the transmembrane domain regions. Such motions may lead to the opening of the receptor. The upper lobes of the LBDs of the ZK bound state have a smaller interface with the amino terminal domains above them and have a better ability to move together. The present study exemplifies the use of dynamics comparison as a tool to study protein function. Proteins 2017; 85:1507-1517. © 2014 Wiley Periodicals, Inc.
Subject(s)
2,3-Diphosphoglycerate/chemistry , Alanine/analogs & derivatives , Excitatory Amino Acid Agonists/chemistry , Hemoglobins/chemistry , Kainic Acid/chemistry , Receptors, AMPA/chemistry , Sequence Alignment/methods , Uracil/chemistry , 2,3-Diphosphoglycerate/metabolism , Alanine/chemistry , Alanine/metabolism , Algorithms , Allosteric Site , Animals , Binding Sites , Excitatory Amino Acid Agonists/metabolism , Halogenation , Hemoglobins/metabolism , Humans , Kainic Acid/metabolism , Ligands , Molecular Dynamics Simulation , Protein Binding , Protein Conformation, alpha-Helical , Protein Conformation, beta-Strand , Protein Interaction Domains and Motifs , Rats , Receptors, AMPA/metabolism , Sequence Homology, Amino Acid , Thermodynamics , Uracil/metabolismABSTRACT
A series of analogues based on serine as lead structure were designed, and their agonist activities were evaluated at recombinant NMDA receptor subtypes (GluN1/2A-D) using two-electrode voltage-clamp (TEVC) electrophysiology. Pronounced variation in subunit-selectivity, potency, and agonist efficacy was observed in a manner that was dependent on the GluN2 subunit in the NMDA receptor. In particular, compounds 15a and 16a are potent GluN2C-specific superagonists at the GluN1 subunit with agonist efficacies of 398% and 308% compared to glycine. This study demonstrates that subunit-selectivity among glycine site NMDA receptor agonists can be achieved and suggests that glycine-site agonists can be developed as pharmacological tool compounds to study GluN2C-specific effects in NMDA receptor-mediated neurotransmission.
Subject(s)
Excitatory Amino Acid Agonists/pharmacology , Receptors, N-Methyl-D-Aspartate/agonists , Animals , Binding Sites , Dose-Response Relationship, Drug , Excitatory Amino Acid Agonists/chemistry , Glycine/metabolism , Glycine/pharmacology , Membrane Potentials/drug effects , Membrane Potentials/physiology , Molecular Docking Simulation , Molecular Dynamics Simulation , Oocytes , Patch-Clamp Techniques , Protein Binding , Protein Multimerization , Receptors, N-Methyl-D-Aspartate/metabolism , Recombinant Proteins/metabolism , Stereoisomerism , Xenopus laevisABSTRACT
Kainate receptors (KARs) consist of a class of ionotropic glutamate receptors, which exert diverse pre- and postsynaptic functions through complex signaling regulating the activity of neural circuits. Whereas numerous small-molecule positive allosteric modulators of the ligand-binding domain of (S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propanoic acid (AMPA) receptors have been reported, no such ligands are available for KARs. In this study, we investigated the ability of three benzothiadiazine-based modulators to potentiate glutamate-evoked currents at recombinantly expressed KARs. 4-cyclopropyl-7-fluoro-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide (BPAM344) potentiated glutamate-evoked currents of GluK2a 21-fold at the highest concentration tested (200 µM), with an EC50 of 79 µM. BPAM344 markedly decreased desensitization kinetics (from 5.5 to 775 ms), whereas it only had a minor effect on deactivation kinetics. 4-cyclopropyl-7-hydroxy-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide (BPAM521) potentiated the recorded peak current amplitude of GluK2a 12-fold at a concentration of 300 µM with an EC50 value of 159 µM, whereas no potentiation of the glutamate-evoked response was observed for 7-chloro-4-(2-fluoroethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide (BPAM121) at the highest concentration of modulator tested (300 µM). BPAM344 (100 µM) also potentiated the peak current amplitude of KAR subunits GluK3a (59-fold), GluK2a (15-fold), GluK1b (5-fold), as well as the AMPA receptor subunit GluA1i (5-fold). X-ray structures of the three modulators in the GluK1 ligand-binding domain were determined, locating two modulator-binding sites at the GluK1 dimer interface. In conclusion, this study may enable the design of new positive allosteric modulators selective for KARs, which will be of great interest for further investigation of the function of KARs in vivo and may prove useful for pharmacologically controlling the activity of neuronal networks.
Subject(s)
Excitatory Amino Acid Agonists/chemistry , Excitatory Amino Acid Agonists/metabolism , Receptors, Kainic Acid/chemistry , Receptors, Kainic Acid/metabolism , Allosteric Regulation/drug effects , Allosteric Regulation/physiology , Animals , Dose-Response Relationship, Drug , HEK293 Cells , Humans , Protein Structure, Secondary , Rats , Receptors, Kainic Acid/agonists , Structure-Activity Relationship , X-Ray DiffractionABSTRACT
The metabotropic glutamate receptor 2 (mGlu2) plays an important role in the presynaptic control of glutamate release and several mGlu2 positive allosteric modulators (PAMs) have been under assessment for their potential as antipsychotics. The binding mode of mGlu2 PAMs is better characterized in functional terms while few data are available on the relationship between allosteric and orthosteric binding sites. Pharmacological studies characterizing binding and effects of two different chemical series of mGlu2 PAMs are therefore carried out here using the radiolabeled mGlu2 agonist 3[H]-LY354740 and mGlu2 PAM 3[H]-2,2,2-TEMPS. A multidimensional approach to the PAM mechanism of action shows that mGlu2 PAMs increase the affinity of 3[H]-LY354740 for the orthosteric site of mGlu2 as well as the number of 3[H]-LY354740 binding sites. 3[H]-2,2,2-TEMPS binding is also enhanced by the presence of LY354740. New residues in the allosteric rat mGlu2 binding pocket are identified to be crucial for the PAMs ligand binding, among these Tyr3.40 and Asn5.46. Also of remark, in the described experimental conditions S731A (Ser5.42) residue is important only for the mGlu2 PAM LY487379 and not for the compound PAM-1: an example of the structural differences among these mGlu2 PAMs. This study provides a summary of the information generated in the past decade on mGlu2 PAMs adding a detailed molecular investigation of PAM binding mode. Differences among mGlu2 PAM compounds are discussed as well as the mGlu2 regions interacting with mGlu2 PAM and NAM agents and residues driving mGlu2 PAM selectivity. This article is part of the Special Issue entitled 'Metabotropic Glutamate Receptors, 5 years on'.
Subject(s)
Excitatory Amino Acid Agonists/metabolism , Excitatory Amino Acid Agonists/pharmacology , Receptors, Metabotropic Glutamate/agonists , Receptors, Metabotropic Glutamate/physiology , Allosteric Regulation/drug effects , Allosteric Regulation/physiology , Animals , Binding Sites/physiology , Bridged Bicyclo Compounds/chemistry , Bridged Bicyclo Compounds/metabolism , Bridged Bicyclo Compounds/pharmacology , Excitatory Amino Acid Agonists/chemistry , Glutamic Acid/metabolism , Glutamic Acid/pharmacology , Humans , Protein Structure, SecondaryABSTRACT
Memory loss observed as a consequence of aging is paralleled by a down-regulation of AMPA-type glutamate receptors (AMPARs) that mediate fast excitatory synaptic transmission. Activation of these receptors enhances long-term potentiation (LTP), a neuronal process demonstrated to be crucial for memory storage and thought to be a cellular substrate of learning and memory. In the present studies, we determined that LTP was reduced in aged rats when compared to young rats and that acute treatment with CX1846, a novel AMPAR positive allosteric modulator, fifteen minutes prior to tetanic stimulation completely reversed the significant deficit in LTP observed in aged rats. These results suggest that CX1846 might be useful for the treatment of age-related memory impairments.
Subject(s)
Aging/drug effects , Excitatory Amino Acid Agonists/pharmacology , Long-Term Potentiation/drug effects , Memory Disorders , Receptors, AMPA/agonists , Aging/physiology , Allosteric Regulation/drug effects , Allosteric Regulation/physiology , Animals , Excitatory Amino Acid Agonists/chemistry , Excitatory Amino Acid Agonists/therapeutic use , Long-Term Potentiation/physiology , Memory Disorders/drug therapy , Rats , Rats, Inbred F344 , Receptors, AMPA/physiology , Treatment OutcomeABSTRACT
The controlled activation of proteins in living cells is an important goal in protein-design research, but to introduce an artificial activation switch into membrane proteins through rational design is a significant challenge because of the structural and functional complexity of such proteins. Here we report the allosteric activation of two types of membrane-bound neurotransmitter receptors, the ion-channel type and the G-protein-coupled glutamate receptors, using coordination chemistry in living cells. The high programmability of coordination chemistry enabled two His mutations, which act as an artificial allosteric site, to be semirationally incorporated in the vicinity of the ligand-binding pockets. Binding of Pd(2,2'-bipyridine) at the allosteric site enabled the active conformations of the glutamate receptors to be stabilized. Using this approach, we were able to activate selectively a mutant glutamate receptor in live neurons, which initiated a subsequent signal-transduction pathway.
Subject(s)
Coordination Complexes/pharmacology , Excitatory Amino Acid Agonists/pharmacology , Receptors, Glutamate/metabolism , Receptors, Ionotropic Glutamate/metabolism , Receptors, Metabotropic Glutamate/metabolism , Allosteric Site , Animals , Calcium/metabolism , Cerebral Cortex/metabolism , Coordination Complexes/chemistry , Coordination Complexes/toxicity , Cyclic AMP Response Element-Binding Protein/metabolism , Excitatory Amino Acid Agonists/chemistry , Excitatory Amino Acid Agonists/toxicity , HEK293 Cells , Histidine/chemistry , Humans , Mutation , Neurons/metabolism , Palladium/chemistry , Phosphorylation , Rats, Sprague-Dawley , Receptors, Glutamate/genetics , Receptors, Ionotropic Glutamate/genetics , Receptors, Metabotropic Glutamate/genetics , Signal TransductionABSTRACT
5-Arylbenzothiadiazine type compounds acting as positive allosteric modulators of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA-PAMs) have received particular attention in the past decade for their nootropic activity and lack of the excitotoxic side effects of direct agonists. Recently, our research group has published the synthesis and biological activity of 7-chloro-5-(3-furanyl)-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide (1), one of the most active benzothiadiazine-derived AMPA-PAMs in vitro to date. However, 1 exists as two stereolabile enantiomers, which rapidly racemize in physiological conditions, and only one isomer is responsible for the pharmacological activity. In the present work, experiments carried out with rat liver microsomes show that 1 is converted by hepatic cytochrome P450 to the corresponding unsaturated derivative 2 and to the corresponding pharmacologically inactive benzenesulfonamide 3. Surprisingly, patch-clamp experiments reveal that 2 displays an activity comparable to that of the parent compound. Molecular modeling studies were performed to rationalize these results. Furthermore, mice cerebral microdialysis studies suggest that 2 is able to cross the blood-brain barrier and increases acetylcholine and serotonin levels in the hippocampus. The experimental data disclose that the achiral hepatic metabolite 2 possesses the same pharmacological activity of its parent compound 1 but with an enhanced chemical and stereochemical stability, as well as an improved pharmacokinetic profile compared with 1.
Subject(s)
Excitatory Amino Acid Agonists/chemistry , Excitatory Amino Acid Agonists/pharmacology , Neurons/drug effects , Receptors, AMPA/metabolism , alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid/chemistry , alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid/pharmacology , Action Potentials/drug effects , Animals , Animals, Newborn , Cells, Cultured , Cerebellum/cytology , Corpus Striatum/drug effects , Furans/chemistry , Furans/pharmacology , Mice , Microdialysis , Models, Molecular , Neurotransmitter Agents/metabolism , Rats , Rats, Sprague-Dawley , Stereoisomerism , Tandem Mass Spectrometry , Thiadiazines/chemistry , Thiadiazines/pharmacologyABSTRACT
Allosteric modulation of metabotropic glutamate (mGlu) receptors offers a promising pharmacological approach to normalize neural circuit dysfunction associated with various psychiatric and neurological disorders. As mGlu receptor allosteric modulators progress through discovery and clinical development, both technical advances and novel tool compounds are providing opportunities to better understand mGlu receptor pharmacology and neurobiology. Recent advances in structural biology are elucidating the structural determinants of mGlu receptor-negative allosteric modulation and supplying the means to resolve active, allosteric modulator-bound mGlu receptors. The discovery and characterization of allosteric modulators with novel pharmacological profiles is uncovering the biological significance of their intrinsic agonist activity, biased mGlu receptor modulation, and novel mGlu receptor heterodimers. The development and exploitation of optogenetic and optopharmacological tools is permitting a refined spatial and temporal understanding of both mGlu receptor functions and their allosteric modulation in intact brain circuits. Together, these lines of research promise to provide a more refined understanding of mGlu receptors and their allosteric modulation that will inform the development of mGlu receptor allosteric modulators as neurotherapeutics in the years to come.
Subject(s)
Brain/drug effects , Drug Design , Drug Discovery/methods , Excitatory Amino Acid Agonists/pharmacology , Receptors, Metabotropic Glutamate/agonists , Animals , Binding Sites , Brain/metabolism , Excitatory Amino Acid Agonists/chemistry , Excitatory Amino Acid Agonists/metabolism , Humans , Optogenetics , Protein Binding , Protein Conformation , Protein Multimerization , Receptors, Metabotropic Glutamate/chemistry , Receptors, Metabotropic Glutamate/metabolism , Structure-Activity Relationship , Synaptic Transmission/drug effectsABSTRACT
Total syntheses of structurally and biologically intriguing natural products relying on new synthetic methodologies are described. This article features cinchona alkaloid-catalyzed asymmetric Morita-Baylis-Hillman reactions, heterocycle syntheses based on rhodium-catalyzed C-H amination and indium-catalyzed Conia-ene reactions, and their utilization for the syntheses of the phoslactomycin family of antibiotics, glutamate receptor agonists and antagonists, and alkaloids with characteristic highly substituted pyrrolidinone core structures.
Subject(s)
Alkaloids/chemical synthesis , Anti-Bacterial Agents/chemical synthesis , Biological Products/chemical synthesis , Chemistry Techniques, Synthetic/methods , Excitatory Amino Acid Agents/chemical synthesis , Lactones/chemical synthesis , Alkaloids/chemistry , Anti-Bacterial Agents/chemistry , Biological Products/chemistry , Catalysis , Cinchona Alkaloids/chemistry , Excitatory Amino Acid Agents/chemistry , Excitatory Amino Acid Agonists/chemical synthesis , Excitatory Amino Acid Agonists/chemistry , Excitatory Amino Acid Antagonists/chemical synthesis , Excitatory Amino Acid Antagonists/chemistry , Indium/chemistry , Lactones/chemistry , Rhodium/chemistryABSTRACT
Understanding the thermodynamics of binding of a lead compound to a receptor can provide valuable information for drug design. The binding of compounds, particularly partial agonists, to subtypes of the α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor is, in some cases, driven by increases in entropy. Using a series of partial agonists based on the structure of the natural product, willardiine, we show that the charged state of the ligand determines the enthalpic contribution to binding. Willardiines have uracil rings with pKa values ranging from 5.5 to 10. The binding of the charged form is largely driven by enthalpy, while that of the uncharged form is largely driven by entropy. This is due at least in part to changes in the hydrogen bonding network within the binding site involving one water molecule. This work illustrates the importance of charge to the thermodynamics of binding of agonists and antagonists to AMPA receptors and provides clues for further drug discovery.